Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Outcome of preoperative concurrent radiation and infusional gemcitabine in locally advanced rectal cancer, a phase 2 trial.
Authors
Shouki Bazarbashi
King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Shouki Bazarbashi , Ahmed Mostafa Gad , Ahmed Ali Badran , Mahmoud Elshenawy , Ali H Aljubran , Ahmad Al Zahrani , Hadeel Al Manae , Abdullah Alsuhaibani , Ahmed Elashwah , Mohammed Neimatallah , Alaa Abdul Jabbar , Luai Ashari , Samar Al Homoud , Hazem Ghebeh , Nasser Alsanea , Mohammed Mohiuddin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02919878
DOI
10.1200/JCO.2022.40.4_suppl.094
Abstract #
94
Poster Bd #
L7
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 2 study of cyclophosphamide (CY), GVAX, pembrolizumab (Pembro), and stereotactic body radiation (SBRT) in patients (pts) with locally advanced pancreas cancer (LAPC).
First Author: Valerie Lee
Poster
2013 Gastrointestinal Cancers Symposium
A randomized phase II study of neoadjuvant chemoradiotherapy with 5-FU/leucovorin or irinotecan/S1 in patients with locally advanced rectal cancer.
First Author: Minkyu Jung
Poster
2011 ASCO Annual Meeting
Efficacy endpoints of RTOG 0247: A randomized phase II study of neoadjuvant capecitabine (C) and irinotecan (I) or C and oxaliplatin (O) with concurrent radiation therapy (RT) for locally advanced rectal cancer.
First Author: S. J. Wong
Poster
2024 ASCO Annual Meeting
Total neoadjuvant therapy with split-course hypofraction radiotherapy combined with CAPOX and envafolimab followed by local excision for locally advanced very low rectal cancer (TRACE-LE): An open-label, single-arm, multicenter, phase II trial.
First Author: Weizhong Jiang